Aurinia Pharmaceuticals (NASDAQ: AUPH) insider transactions
In the twelve months to 10 November 2026, executives and directors of Aurinia Pharmaceuticals reported 2 open-market sales of 32,914 shares ($546,373) and 11 open-market purchases of 1,714,606 shares ($25.1m), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 10 September 2026 | Robertson Stephen P. | Chief Legal Officer | Open-market sale | −11,939 | $15.95 | 588,848 | Form 4 |
| 21 August 2026 | Robertson Stephen P. | Chief Legal Officer | Open-market sale | −20,975 | $16.97 | 600,787 | Form 4 |
| 2 June 2026 | Tang Kevin | Chief Executive Officer | Open-market purchase | +206,005 | $15.28 | 13,044,106 | Form 4 |
| 1 June 2026 | Tang Kevin | Chief Executive Officer | Open-market purchase | +343,521 | $15.28 | 12,838,002 | Form 4 |
| 1 June 2026 | Tang Kevin | Chief Executive Officer | Open-market purchase | +99 | $15.34 | 12,838,101 | Form 4 |
| 29 May 2026 | Tang Kevin | Chief Executive Officer | Open-market purchase | +2,299 | $15.35 | 12,231,799 | Form 4 |
| 29 May 2026 | Tang Kevin | Chief Executive Officer | Open-market purchase | +262,682 | $15.31 | 12,494,481 | Form 4 |
| 18 May 2026 | Hearne Michael S | Chief Financial Officer | Grant or award | +116,144 | — | 116,144 | Form 4 |
| 18 May 2026 | Robertson Stephen P. | Chief Legal Officer | Grant or award | +115,541 | — | 621,402 | Form 4 |
| 18 May 2026 | Cole Ryan | Chief Operating Officer | Grant or award | +116,144 | — | 116,144 | Form 4 |
| 6 March 2026 | Keenan Greg | SVP, Chief Medical Officer | Shares withheld for tax | −8,069 | $14.32 | 154,449 | Form 4 |
| 3 March 2026 | Tang Kevin | Director | Open-market purchase | +184,208 | $14.22 | 12,229,500 | Form 4 |
| 2 March 2026 | Tang Kevin | Director | Open-market purchase | +83,561 | $14.33 | 11,929,500 | Form 4 |
| 2 March 2026 | Tang Kevin | Director | Open-market purchase | +115,792 | $14.21 | 12,045,292 | Form 4 |
| 2 March 2026 | Robertson Stephen P. | EVP, General Counsel | Shares withheld for tax | −36,525 | $14.21 | 505,861 | Form 4 |
| 2 March 2026 | Greenleaf Peter | Chief Executive Officer | Shares withheld for tax | −100,890 | $14.21 | 1,840,379 | Form 4 |
| 2 March 2026 | Donley Matthew Maxwell | Chief Operating Officer | Shares withheld for tax | −40,761 | $14.21 | 680,299 | Form 4 |
| 2 March 2026 | Miller Joseph M | Chief Financial Officer | Shares withheld for tax | −37,511 | $14.21 | 576,421 | Form 4 |
| 27 February 2026 | Tang Kevin | Director | Open-market purchase | +300,000 | $13.90 | 11,629,500 | Form 4 |
| 27 February 2026 | Tang Kevin | Director | Open-market purchase | +214,839 | $14.12 | 11,844,339 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Aurinia Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.